Yüksel Ürün, Professor of Medical Oncology at Ankara University School of Medicine, shared on X:
“Practice-changing results.
Now the conversation shifts from whether to use EV + pembrolizumab to how to use it.
Who truly benefits?
What is the optimal management after pCR?
Can we preserve the bladder in selected responders?
And how do we incorporate patient preferences into these decisions? ”
Title: Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
Authors: Matthew D. Galsky, Begoña P. Valderrama, Marco Maruzzo, Albert Font, Tudor Ciuleanu, Jonathan Chatzkel, Takuya Koie
Other articles about Bladder Cancer on OncoDaily.